Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$307.80 USD

307.80
3,427,831

+6.66 (2.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $307.00 -0.80 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (175 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?

by Zacks Equity Research

McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.

    Zacks Equity Research

    IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?

    by Zacks Equity Research

    IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.

      Zacks Equity Research

      What's in Store for Express Scripts (ESRX) in Q2 Earnings?

      by Zacks Equity Research

      Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.

        Zacks Equity Research

        Baxter International (BAX) Q2 Earnings: What's in Store?

        by Zacks Equity Research

        Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.

          Zacks Equity Research

          Varian Medical (VAR) Q3 Earnings: Is a Surprise in Store?

          by Zacks Equity Research

          Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.

            Zacks Equity Research

            Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?

            by Zacks Equity Research

            Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.

              Zacks Equity Research

              Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings?

              by Zacks Equity Research

              Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.

                Zacks Equity Research

                GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?

                by Zacks Equity Research

                We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.

                  Zacks Equity Research

                  Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?

                  by Zacks Equity Research

                  Edwards Lifesciences (EW) will likely ride high in Q2 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve space.

                    Zacks Equity Research

                    Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?

                    by Zacks Equity Research

                    Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.